Assessing blood levels of mediators in COVID-19 patients
COVID-19 RELATED SUBMISSION: VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
This study is trying to see how certain substances in the blood of COVID-19 patients might affect their health and why some people with heart issues get sicker than others.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT04587323 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the blood levels of vasoactive mediators that may influence pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19. The study will correlate these levels with various disease outcomes, including ICU admission, length of ventilatory support, and instances of respiratory, kidney, and heart failure. By comparing patients with preexisting cardiovascular conditions to those without, the research seeks to understand why some individuals experience more severe symptoms. The findings could provide insights into the pathophysiology of COVID-19 and its impact on patients with underlying health issues.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have tested positive for COVID-19 and have available blood specimens.
Not a fit: Patients under 18 years old or those without a blood specimen will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of COVID-19 severity and inform treatment strategies for affected patients.
How similar studies have performed: While this study explores a specific pathway in COVID-19, similar approaches have shown promise in understanding other respiratory infections, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Positive test for COVID-19 (SARS-CoV-2 infection) * \>=18 years * Blood (plasma) specimen(s) available in the CCTS biorepository Exclusion Criteria: * \<18 years * Lack of blood specimen
Where this trial is running
Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama, United States (Recruiting)
Study contacts
- Principal investigator: Dylan Addis, MD — University of Alabama at Birmingham
- Study coordinator: Dylan Addis, MD
- Email: dylanaddis@uabmc.edu
- Phone: 919-812-5107
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.